Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence

Samuele Renzi, Orli Michaeli, Hector Salvador, Daniel Alderete, Nicolas Fernandez Ponce, Michal Zapotocky, Jordan R. Hansford, Vajiranee S. Malalasekera, Helen Toledano, Bryan Maguire, Eric Bouffet, Vijay Ramaswamy, Lorena V. Baroni

Research output: Contribution to journalArticlepeer-review

Abstract

Seventeen children at six institutions with neurofibromatosis type 2 (NF2)-related vestibular schwannomas received bevacizumab. Eight of the 13 patients with initial hearing loss (61%) showed objective hearing improvement within six months of treatment. No patients showed hearing deterioration during therapy; however, only two patients showed objective radiological response. Seven of eight patients had tumor progression or worsening hearing loss upon cessation of treatment. Bevacizumab was well tolerated with no patients discontinuing therapy. Bevacizumab appears to postpone hearing loss in childhood NF2-associated vestibular schwannomas, but responses are not durable, suggesting that either longer maintenance therapy or new strategies are required.

Original languageEnglish
Article numbere28228
JournalPediatric Blood and Cancer
Volume67
Issue number5
DOIs
StatePublished - 1 May 2020

Keywords

  • NF2
  • bevacizumab
  • brain tumors
  • vestibular schwannomas

Fingerprint

Dive into the research topics of 'Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence'. Together they form a unique fingerprint.

Cite this